Magazine Pharmacology Thrapeutique Quiz Forums Sick of ads on Pharmacorama? Home Magazine blurred vision News medications "receivers CGRP antagonists, and olcgpant telcagpant in the migraine attack Brief Summary of 2015 | 14 | 13 | 12 | 11 | 10 | 9 | 8 | 7 | 6 | 5 | 4 | 3 | 2 | 1 Latest Articles Suvorexant, Belsomra, (USA), new hypnotic treatment of insomnia New Ramucirumab in stomach cancer and lung New naltrexone + bupropion, Mysimba * in the treatment of obesity Nintdanib New FOEN * in the treatment of idiopathic pulmonary fibrosis blurred vision (USA) For better use of the medicinal product: renovate the RCP + paclitaxel versus paclitaxel Ramucirumab alone in the gastric cancer and gastro-oesophageal Panobinostat, anticancreux being Dulaglutide studies, GLP-1 mimtique, antidiabtique, blurred vision sold under the name of the USA Trulicity * Pub antagonists receivers CGRP and olcgpant telcagpant in the migraine attack blurred vision Author: Pierre Allain Date: 13-1-2009
CGRP antagonists of receivers blurred vision such as BIBN409BS or olcgpant have montrs active in clinical trials in the treatment of migraine attack but it was administered intravenously, which does is not very convenient since the migraine attack usually treats home.
The Lancet September 20, 2008 reported the results of a clinical trial of a new antagonist CGRP receivers, the telcagpant, orally active. The telcagpant, the 300 mg dose does a comparable efficiency blurred vision that zolmitriptan, Zomig *, a dose of 5 mg, with a bit less of adverse reactions. The telcagpant could therefore come if these favorable results are Confirms, broaden the list of medicines that may be utiliss in the treatment of migraine attacks.
CGRP antagonists of receivers blurred vision such as BIBN409BS or olcgpant have montrs active in clinical trials in the treatment of migraine attack but it was administered intravenously, which does is not very convenient since the migraine attack usually treats home.
The Lancet September 20, 2008 reported the results of a clinical trial of a new antagonist CGRP receivers, the telcagpant, orally active. The telcagpant, the 300 mg dose does a comparable efficiency blurred vision that zolmitriptan, Zomig *, a dose of 5 mg, with a bit less of adverse reactions. The telcagpant could therefore come if these favorable results are Confirms, broaden the list of medicines that may be utiliss in the treatment of migraine attacks.
No comments:
Post a Comment